{"id":3465,"date":"2023-07-18T17:49:03","date_gmt":"2023-07-18T23:49:03","guid":{"rendered":"https:\/\/udibi6748.live-website.com\/?page_id=3465"},"modified":"2023-07-18T17:50:50","modified_gmt":"2023-07-18T23:50:50","slug":"anti-sars-cov-2","status":"publish","type":"page","link":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/","title":{"rendered":"Anti SARS-CoV-2"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;Anti SARS-CoV-2&#8243; font_container=&#8221;tag:h2|font_size:35|text_align:left|color:%230d1250&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal&#8221;][vc_column_text]In response to the health emergency and health priorities in Mexico, the National Polytechnic Institute and GlobalBio Inc. focused on the development of monoclonal therapeutic antibodies to neutralize SARS-CoV-2. Two antibody discovery platforms were created: ALTHEA Gold+ Libraries\u2122, a semi-synthetic library, and ALTHEA SARS-CoV-2 Libraries\u2122, constructed from the repertoire of a convalescent COVID-19 patient. Both libraries generated high-affinity antibodies against SARS-CoV-2 through screening with the RBD antigen from the Wuhan isolate.<\/p>\n<p>&nbsp;<\/p>\n<p>Two lead antibodies were selected from the obtained results: UDIZ-0004 and D1. UDIZ-004, derived from ALTHEA Gold+ Libraries\u2122, neutralizes the Wuhan isolate and the Delta variant. This antibody laid the foundation for the development of anti-SARS-CoV-2 antibodies. D1, obtained from ALTHEA SARS-CoV-2 Libraries\u2122, neutralizes the Wuhan, Delta, and Omicron variants in vitro. Additionally, it was demonstrated that D1 prevents 100% of deaths in transgenic animals infected with the Wuhan isolate.<\/p>\n<p>&nbsp;<\/p>\n<p>This project concluded with the development of the Phase 1 clinical protocol, as the pandemic and health emergency came to an end. However, this effort allowed UDIBI to establish a platform for the discovery and development of antibodies in the non-clinical stage.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;Anti SARS-CoV-2&#8243; font_container=&#8221;tag:h2|font_size:35|text_align:left|color:%230d1250&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal&#8221;][vc_column_text]In response to the health emergency and health priorities in Mexico, the National Polytechnic Institute and GlobalBio Inc. focused on the development of monoclonal therapeutic antibodies to neutralize SARS-CoV-2. Two antibody discovery platforms were created: ALTHEA Gold+ Libraries\u2122, a semi-synthetic library, and ALTHEA SARS-CoV-2 Libraries\u2122, constructed from the repertoire of a convalescent COVID-19 patient. Both libraries [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"pmpro_default_level":"","footnotes":""},"class_list":["post-3465","page","type-page","status-publish","hentry","pmpro-has-access"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anti SARS-CoV-2 - UDIBI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti SARS-CoV-2 - UDIBI\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_custom_heading text=&#8221;Anti SARS-CoV-2&#8243; font_container=&#8221;tag:h2|font_size:35|text_align:left|color:%230d1250&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal&#8221;][vc_column_text]In response to the health emergency and health priorities in Mexico, the National Polytechnic Institute and GlobalBio Inc. focused on the development of monoclonal therapeutic antibodies to neutralize SARS-CoV-2. Two antibody discovery platforms were created: ALTHEA Gold+ Libraries\u2122, a semi-synthetic library, and ALTHEA SARS-CoV-2 Libraries\u2122, constructed from the repertoire of a convalescent COVID-19 patient. Both libraries [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/\" \/>\n<meta property=\"og:site_name\" content=\"UDIBI\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-18T23:50:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/\",\"url\":\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/\",\"name\":\"Anti SARS-CoV-2 - UDIBI\",\"isPartOf\":{\"@id\":\"https:\/\/udibi.com.mx\/en\/#website\"},\"datePublished\":\"2023-07-18T23:49:03+00:00\",\"dateModified\":\"2023-07-18T23:50:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/udibi.com.mx\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti SARS-CoV-2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/udibi.com.mx\/en\/#website\",\"url\":\"https:\/\/udibi.com.mx\/en\/\",\"name\":\"UDIBI\",\"description\":\"IPN\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/udibi.com.mx\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti SARS-CoV-2 - UDIBI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/","og_locale":"en_US","og_type":"article","og_title":"Anti SARS-CoV-2 - UDIBI","og_description":"[vc_row][vc_column][vc_custom_heading text=&#8221;Anti SARS-CoV-2&#8243; font_container=&#8221;tag:h2|font_size:35|text_align:left|color:%230d1250&#8243; google_fonts=&#8221;font_family:Montserrat%3Aregular%2C700|font_style:700%20bold%20regular%3A700%3Anormal&#8221;][vc_column_text]In response to the health emergency and health priorities in Mexico, the National Polytechnic Institute and GlobalBio Inc. focused on the development of monoclonal therapeutic antibodies to neutralize SARS-CoV-2. Two antibody discovery platforms were created: ALTHEA Gold+ Libraries\u2122, a semi-synthetic library, and ALTHEA SARS-CoV-2 Libraries\u2122, constructed from the repertoire of a convalescent COVID-19 patient. Both libraries [&hellip;]","og_url":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/","og_site_name":"UDIBI","article_modified_time":"2023-07-18T23:50:50+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/","url":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/","name":"Anti SARS-CoV-2 - UDIBI","isPartOf":{"@id":"https:\/\/udibi.com.mx\/en\/#website"},"datePublished":"2023-07-18T23:49:03+00:00","dateModified":"2023-07-18T23:50:50+00:00","breadcrumb":{"@id":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/udibi.com.mx\/en\/anti-sars-cov-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/udibi.com.mx\/en\/"},{"@type":"ListItem","position":2,"name":"Anti SARS-CoV-2"}]},{"@type":"WebSite","@id":"https:\/\/udibi.com.mx\/en\/#website","url":"https:\/\/udibi.com.mx\/en\/","name":"UDIBI","description":"IPN","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/udibi.com.mx\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/comments?post=3465"}],"version-history":[{"count":2,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3465\/revisions"}],"predecessor-version":[{"id":3467,"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/pages\/3465\/revisions\/3467"}],"wp:attachment":[{"href":"https:\/\/udibi.com.mx\/en\/wp-json\/wp\/v2\/media?parent=3465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}